1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Erectile Dysfunction Treatment Drugs Market
2.2. Global Erectile Dysfunction Treatment Drugs Market, By Drug, 2023 (US$ Million)
2.3. Global Erectile Dysfunction Treatment Drugs Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Erectile Dysfunction Treatment Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Erectile Dysfunction Treatment Drugs Market Vendors
3.2. Strategies Adopted by Erectile Dysfunction Treatment Drugs Market Vendors
3.3. Key Industry Strategies
4. Erectile Dysfunction Treatment Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Erectile Dysfunction Treatment Drugs Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Phosphodiesterase Type 5 Inhibitors (PDE5 Inhibitors)
5.3.1.1. Sildenafil (Viagra)
5.3.1.2. Tadalafil (Adcirca, Cialis)
5.3.1.3. Vardenafil (Levitra, Staxyn)
5.3.1.4. Avanafil (Stendra)
5.3.2. Prostaglandin E1
5.3.2.1. Alprostadil (Caverject, Edex, Muse, Prostin VR Pediatric)
5.3.3. Others


6. North America Erectile Dysfunction Treatment Drugs Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
6.3.Erectile Dysfunction Treatment Drugs Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)

7. UK and European Union Erectile Dysfunction Treatment Drugs Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.Erectile Dysfunction Treatment Drugs Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)

8. Asia Pacific Erectile Dysfunction Treatment Drugs Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.Erectile Dysfunction Treatment Drugs Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)

9. Latin America Erectile Dysfunction Treatment Drugs Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
9.3.Erectile Dysfunction Treatment Drugs Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)

10. Middle East and Africa Erectile Dysfunction Treatment Drugs Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
10.3.Erectile Dysfunction Treatment Drugs Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Erectile Dysfunction Treatment Drugs Market: By Drug, 2022-2032, USD (Million)

11. Company Profile
11.1. Apricus Biosciences
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Bayer AG
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Dong-A Pharmaceutical Co. Ltd
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Eli Lilly and Company
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Johnson & Johnson Services
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Meda Pharmaceuticals
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Pfizer Inc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Vivus, Inc.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives